cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Belite Bio Inc Adr
2 watching
Current Price
$0
$0.07
(0.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
162.66M
52-Week High
52-Week High
44.7
52-Week Low
52-Week Low
8.8
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization162.66M
icon52-Week High44.7
icon52-Week Low8.8
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Belite Bio Inc Adr do?
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Read More
News & Events about Belite Bio Inc Adr.
Globe Newswire
2 months ago
Tinlarebant (a/k/a LBS-008) is Belite Bios orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD)There are currently no approved treatments for STGD1 and Dry ...
Globe Newswire
4 months ago
1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 to be presented SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, ...
Globe Newswire
4 months ago
LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease (STGD1) and Dry AMD patientsA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoingThe Phase 3 trial ...
Globe Newswire
5 months ago
LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoingThe Phase 3, Multi-center, Randomized, Double Masked, Placebo Controlled ...
Globe Newswire
6 months ago
-LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD-A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing-The Phase 3, Multicenter, Randomized, Double Masked, Placebo ...
Frequently Asked Questions
Frequently Asked Questions
What is Belite Bio Inc Adr share price today?
plus_minus_icon
Can Indians buy Belite Bio Inc Adr shares?
plus_minus_icon
How can I buy Belite Bio Inc Adr shares from India?
plus_minus_icon
Can Fractional shares of Belite Bio Inc Adr be purchased?
plus_minus_icon
What are the documents required to start investing in Belite Bio Inc Adr stocks?
plus_minus_icon
What is today’s traded volume of Belite Bio Inc Adr?
plus_minus_icon
What is today’s market capitalisation of Belite Bio Inc Adr?
plus_minus_icon
What is the 52-Week High and Low Range of Belite Bio Inc Adr?
plus_minus_icon
What percentage is Belite Bio Inc Adr down from its 52-Week High?
plus_minus_icon
What percentage is Belite Bio Inc Adr up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.07
(0.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00